The stock of PharMerica Corporation (NYSE:PMC) hit a new 52-week low and has $19.48 target or 5.00% below today’s $20.50 share price. The 7 months bearish chart indicates high risk for the $633.33M company. The 1-year low was reported on Nov, 3 by Barchart.com. If the $19.48 price target is reached, the company will be worth $31.67M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 991,334 shares traded hands or 220.26% up from the average. PharMerica Corporation (NYSE:PMC) has risen 8.69% since April 1, 2016 and is uptrending. It has outperformed by 7.47% the S&P500.
Analysts await PharMerica Corporation (NYSE:PMC) to report earnings on November, 4. They expect $0.51 EPS, up 45.71% or $0.16 from last year’s $0.35 per share. PMC’s profit will be $15.76M for 10.05 P/E if the $0.51 EPS becomes a reality. After $0.47 actual EPS reported by PharMerica Corporation for the previous quarter, Wall Street now forecasts 8.51% EPS growth.
PharMerica Corporation (NYSE:PMC) Ratings Coverage
Out of 3 analysts covering Pharmerica (NYSE:PMC), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. Pharmerica has been the topic of 6 analyst reports since August 10, 2015 according to StockzIntelligence Inc. The company was maintained on Monday, August 10 by Barrington Research. UBS upgraded the shares of PMC in a report on Monday, August 10 to “Neutral” rating. Barrington Research maintained the stock with “Outperform” rating in Tuesday, May 10 report. The stock of PharMerica Corporation (NYSE:PMC) has “Hold” rating given on Monday, August 17 by Zacks. The firm has “Buy” rating given on Tuesday, June 7 by Bank of America. The stock has “Neutral” rating given by UBS on Monday, March 14.
According to Zacks Investment Research, “PharMerica Corporation is an institutional pharmacy services provider dedicated to providing quality customer service and innovative pharmacy solutions to institutional customers and patients in long-term care settings. PharMerica is a public company formed through the combination of the institutional pharmacy business of national healthcare services company Kindred Healthcare, Inc. and pharmaceutical services company AmerisourceBergen Corporation. As a result of this combination, PharMerica ranks as an industry-leading U.S. provider of institutional pharmacy services in terms of annual revenues.”
Insitutional Activity: The institutional sentiment decreased to 1.08 in Q2 2016. Its down 0.03, from 1.11 in 2016Q1. The ratio dived, as 18 funds sold all PharMerica Corporation shares owned while 53 reduced positions. 27 funds bought stakes while 50 increased positions. They now own 28.21 million shares or 1.34% less from 28.59 million shares in 2016Q1.
Moreover, National Bank & Trust Of America De has 0% invested in PharMerica Corporation (NYSE:PMC) for 227,197 shares. Tfs Cap Ltd Limited Liability Company has 77,166 shares for 0.35% of their US portfolio. Princeton Alpha Lp holds 8,689 shares or 0.04% of its portfolio. Bnp Paribas Arbitrage holds 10,303 shares or 0% of its portfolio. Nordea Mgmt Ab owns 62,200 shares or 0% of their US portfolio. Bogle Investment Management L P De holds 0.02% or 14,449 shares in its portfolio. Amer International Gp has invested 0% of its portfolio in PharMerica Corporation (NYSE:PMC). Reilly Finance Advsrs Ltd Liability Com last reported 8 shares in the company. Strs Ohio owns 32,000 shares or 0% of their US portfolio. Dimensional Fund Advsrs L P holds 0.04% of its portfolio in PharMerica Corporation (NYSE:PMC) for 2.58 million shares. Blackrock Mngmt holds 0% or 141,192 shares in its portfolio. Millennium Mgmt Ltd Liability Company holds 222,210 shares or 0.01% of its portfolio. Bridgeway Management accumulated 0.02% or 42,050 shares. State Of Tennessee Treasury Department holds 0% of its portfolio in PharMerica Corporation (NYSE:PMC) for 24,067 shares. Schwab Charles Mgmt Inc owns 189,480 shares or 0.01% of their US portfolio.
More notable recent PharMerica Corporation (NYSE:PMC) news were published by: Businesswire.com which released: “PharMerica Corporation Announces Planned Retirement of Chief Financial Officer …” on August 09, 2016, also Businesswire.com with their article: “PharMerica Corporation Announces Fourth Quarter and Year-End 2015 Earnings …” published on February 09, 2016, Fool.com published: “Why PharMerica Soared 13.4% Today” on August 25, 2016. More interesting news about PharMerica Corporation (NYSE:PMC) were released by: Prnewswire.com and their article: “PharMerica Joins DC-Based Senior Care Pharmacy Coalition (SCPC) Citing Need …” published on August 16, 2016 as well as Businesswire.com‘s news article titled: “PharMerica Provides Update on AmerisourceBergen Litigation” with publication date: April 04, 2016.
PMC Company Profile
PharMerica Corporation, incorporated on October23, 2006, is an institutional pharmacy services company. The Firm services healthcare facilities, provides pharmacy management services to hospitals, provides specialty infusion services to patients outside a hospital setting and offers the national oncology pharmacy in the United States. The Firm has three divisions: institutional pharmacy, specialty infusion services and specialty oncology pharmacy. The Company’s core business institutional pharmacy segment provides pharmacy services and products to residents and patients in skilled nursing facilities, nursing centers, assisted living facilities, hospitals and other long-term alternative care settings. The Company’s specialty infusion services segment provides specialty infusion services focused on providing pharmaceutical products and clinical services to patients in client facilities, hospice and outside of hospital or nursing home settings. The Company’s specialty oncology pharmacy segment provides dispensing of oncology drugs, care management and other related services to patients, oncology practices and hospitals.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.